一种Galbulimima类化合物的双向修饰识别了选择性阿片类联体
Florian Martin Zielke1, Stone Woo1,2, Samuel Kasmali1,2
1Department of Chemistry, Scripps Research, La Jolla, California 92037, United States.
ACS central science
|September 2, 2025
概括
研究人员将新型阿片类抗体GB18优化为选择性卡帕阿片类受体 (KOR) 激动剂. 这些化合物有望开发具有改善副作用的新疼痛疗法.
科学领域:
- 医学化学
- 神经科学
- 药理学
背景情况:
- GB18是一种新发现的天然类化合物,作为和类受体对抗剂.
- 片受体调节对于治疗疼痛至关重要, 但目前的治疗方法面临副作用的挑战.
研究的目的:
- 将阿片类抗体GB18多样化和优化为具有改善药理特征的新型配体.
- 探索和卡帕阿片类受体相互作用的结构-活性关系.
- 评估优化化合物的体内疗效和行为效应.
主要方法:
- 化学合成涉及皮皮里丁与皮里丁的替代和化学选择性交叉合反应.
- 在体外受体结合和功能测试以确定亲和力,疗效和选择性 (mu-vs- kappa- opioid受体).
- 在小鼠体内研究,包括在开放场测试中评估大脑透率和行为反应.
主要成果:
- 用皮里丁替换GB18从对抗性转变为部分激动性,增加了卡帕阿片类受体的选择性.
- 开发具有偏差G蛋白与β-arrestin2信号的低至亚纳米KOR选择性全激应剂.
- 在没有镇静剂的情况下,在小鼠中表现出脑透和焦虑类探索行为,与G蛋白信号偏好增加相关.
结论:
- GB18及其类似物是开发新型阿片类药物治疗的可操作的支架.
- 优化可以对药物特性进行微调,从而可能导致更安全,更有效的疼痛管理策略.
- 卡帕阿片类受体的偏激性可能提供一种途径来分离所需的治疗效果和不良效果.
更多相关视频
07:48Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
8.9K
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
2.8K
相关概念视频
Opioid Receptors: Overview
1.8K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.8K
Analgesia and Pain Management
788
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
788
Opioid Analgesics: Synthetic and Semisynthetic Opioids
421
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
421
Opioid Analgesics: Morphine and Other Natural Cogeners
361
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
361
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
